Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release.

Magnetic resonance imaging (MRI) can provide detailedhigh-resolution, tomographic information of disease tissue inreal time and in vivo. Hence, it has become a powerfuldiagnostic tool for detecting the stages of primary andrecurrent solid tumors and for the assessment of suitabletreatment regimens. Therefore, MRI is a suitable techniquefor use in conjunction with theranostic platforms for the post-treatment evaluation of solid tumors.MRI studies are often conducted by using paramagneticGd

[1]  D. Maysinger,et al.  Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles , 2003, Science.

[2]  K. Bhakoo,et al.  Application of MRI to Cell Tracking , 2008 .

[3]  R. Bowtell,et al.  Medical imaging: MRI rides the wave , 2009, Nature.

[4]  W. Plunkett,et al.  Preclinical characteristics of gemcitabine , 1995, Anti-cancer drugs.

[5]  D. Tzemach,et al.  Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. , 1999, Anti-cancer drugs.

[6]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[7]  K. Goa,et al.  Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. , 1997, Drugs.

[8]  D. Maysinger,et al.  Cellular Internalization of Poly(ethylene oxide)-b-poly(ε-caprolactone) Diblock Copolymer Micelles , 2002 .

[9]  Robert E Lenkinski,et al.  PARACEST agents: modulating MRI contrast via water proton exchange. , 2003, Accounts of chemical research.

[10]  M. Brandl,et al.  Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels , 2002, Cancer Chemotherapy and Pharmacology.

[11]  T. Allen.  Liposomal Drug Formulations , 1998, Drugs.

[12]  S. Nguyen,et al.  "Clickable" polymer-caged nanobins as a modular drug delivery platform. , 2009, Journal of the American Chemical Society.

[13]  T. Meade,et al.  Synthesis of multimeric MR contrast agents for cellular imaging. , 2008, Journal of the American Chemical Society.

[14]  T. Meade,et al.  Cellular delivery of MRI contrast agents. , 2004, Chemistry & biology.

[15]  C. Cass,et al.  The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs , 2007, Cancer and Metastasis Reviews.

[16]  J. Reid,et al.  Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Elke S. Bergmann-Leitner,et al.  Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner] , 2005 .

[18]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[19]  H. Kindler,et al.  Chemotherapy for advanced pancreatic cancer: Past, present, and future , 2005, Current oncology reports.

[20]  S. Nguyen,et al.  Synthesis and In vitro activity of ROMP-based polymer nanoparticles. , 2009, Journal of materials chemistry.

[21]  Theresa M. Allen,et al.  Pharmacokinetics of long-circulating liposomes , 1995 .

[22]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[23]  H. Enoch,et al.  Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[25]  S. Nguyen,et al.  Polymer-caged lipsomes: a pH-responsive delivery system with high stability. , 2007, Journal of the American Chemical Society.

[26]  S. Aime,et al.  Biodistribution of gadolinium‐based contrast agents, including gadolinium deposition , 2009, Journal of magnetic resonance imaging : JMRI.

[27]  H. Hori,et al.  Sensitivity to Gemcitabine and Its Metabolizing Enzymes in Neuroblastoma , 2005, Clinical Cancer Research.

[28]  Zahi A Fayad,et al.  Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. , 2004, Journal of the American Chemical Society.

[29]  A. Mazo,et al.  Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  I. Tannock,et al.  Acid pH in tumors and its potential for therapeutic exploitation. , 1989, Cancer research.

[31]  Sergio Grinstein,et al.  Sensors and regulators of intracellular pH , 2010, Nature Reviews Molecular Cell Biology.

[32]  Francis Vocanson,et al.  Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. , 2008, Journal of the American Chemical Society.

[33]  L. Cattel,et al.  Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. , 2006, Molecular pharmaceutics.

[34]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[35]  M. Rosenblum,et al.  Detecting and Treating Cancer with Nanotechnology , 2012, Molecular Diagnosis & Therapy.

[36]  M. Botta,et al.  High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: nanosized MRI contrast agents. , 2008, Journal of the American Chemical Society.

[37]  M. Yessine,et al.  Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. , 2004, Advanced drug delivery reviews.

[38]  Chad A Mirkin,et al.  Multimodal gadolinium-enriched DNA-gold nanoparticle conjugates for cellular imaging. , 2009, Angewandte Chemie.

[39]  Thomas J Meade,et al.  Bioresponsive, cell-penetrating, and multimeric MR contrast agents. , 2009, Accounts of chemical research.

[40]  Luke G Green,et al.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.

[41]  Jinming Gao,et al.  Theranostic nanomedicine for cancer. , 2008, Nanomedicine.

[42]  Jason R McCarthy,et al.  The future of theranostic nanoagents. , 2009, Nanomedicine.

[43]  Peter Caravan,et al.  Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. , 2006, Chemical Society reviews.

[44]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[45]  C. Cass,et al.  The Role of Human Nucleoside Transporters in Cellular Uptake of 4′-Thio-β-d-arabinofuranosylcytosine and β-d-Arabinosylcytosine , 2006, Molecular Pharmacology.

[46]  Stefan Vogt,et al.  DNA-TiO2 nanoconjugates labeled with magnetic resonance contrast agents. , 2007, Journal of the American Chemical Society.